Details up front: 97.6% · dulaglutide.
This should be a straightforward calculation and I keep getting two different answers.
The numbers are arbitrary; the method is what I am after.
What is the general form of this calculation?
97.6 per cent is at the top of what stepwise synthesis delivers on a chain this long, and it is reachable rather than fictional. Every coupling is high-yielding and none is quantitative, so the deletion and truncation sequences that survive purification are what occupies the remaining 2.4 per cent. Above roughly 98 per cent you are fighting the purification rather than the synthesis, which is why a 97.6 per cent figure on dulaglutide deserves a method question — column, gradient, wavelength — rather than either belief or dismissal.
Purity is a method-dependent figure, and that is not a limitation of the measurement, it is a property of what the measurement actually answers.
The fraction of your main peak that is actually your target versus isomers, fragments or related sequences is invisible without complementary identity testing.
| Component | Typical share | Counted in purity? | Counted in content? |
|---|---|---|---|
| Target peptide | 88–94 % | Yes, as main peak | Yes |
| Related impurities | 1–3 % | Yes, as other peaks | No |
| Counter-ion (TFA or acetate) | 2–8 % | No | No |
| Residual water | 2–6 % | No | No |
| Bulking agent, if present | 0–40 % | No | No |
The part that matters: sample solvent strength affects peak shape — if you inject in strong solvent on a gradient starting in weak solvent, the solvent peak can distort your main peak or create a false shoulder.
Published side-by-side method comparisons show that a two-point difference in purity on the same vial is easily explained by method choice alone.
The practical summary: ask for the chromatogram and the method, and ignore the headline number until you have both.
Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.
Browse resultsThe single most important distinction is between what purity measures — the fraction of detected material that is your target — and what you actually want to know — how much of the material in the vial is your target.
Column pore size affects mass transfer — a 100 Angstrom packing on a 5 kDa peptide restricts diffusion, broadening the peak and potentially hiding small impurities in the shoulders.
Worth being precise here: buffer versus acid in the mobile phase changes the ionisation state of basic and acidic residues, shifting retention and selectivity — same vial, potentially different separation.
The ICH Q3A impurity thresholds and the relevant pharmacopoeial chapters all specify method validation requirements that almost no research-grade certificate claims to meet.
If you are ranking vendors, specify a method and have all samples tested at the same place.
edited 2 Jun 2025 by Dr_Rosalind_Achebe — removed a claim I could not source
Mechanically, understanding purity requires separating the chemistry from the method from the reporting convention, and the three are not independent.
Retention time is sequence-specific and method-specific, so comparing your result to a supplier value using a different method is meaningless without method documentation.
Tailing factor measures peak shape, and a badly tailing peak spreads into the region where small impurities live, forcing tangent-skim integration that assigns tail area to the main peak.
The caveat is that purity without identity is only half an answer — a high purity does not mean the peak is actually what you think it is.
Compare purity within a single laboratory on the same method, never across laboratories.
The honest answer is that the achievable range of plausible purity figures for a given vial is wider than most people expect.
Temperature affects the dynamics of molecular conformation, and if a peptide has proline residues that interconvert on the chromatographic timescale, the peak will split or shoulder at low temperature and collapse at high temperature.
The Arrhenius relationship for peptide degradation is the basis of accelerated stability testing and also governs how quickly methods drift with temperature.
If you only pay for one test, pay for quantified content. Purity is the number everyone quotes and content is the number that changes what you do.
Start from what the detector sees, because that tells you what the number means.
Integration of the shoulder — whether you use perpendicular drop or tangent skim — determines what area gets assigned to the main peak versus the impurity table.
Proline conformer interconversion kinetics are well-characterised and the half-life is of the same order as the chromatographic peak width at room temperature.
In practice: ask for the chromatogram, check the method section, check the lot number against the vial, and set your accept threshold before you see the result rather than after.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.